Beijing Scitop Bio-tech Co., Ltd. (SHE:300858)

Market Cap	4.95B +47.5%
Revenue (ttm)	351.47M +16.8%
Net Income	99.40M +7.3%
EPS	0.38 +8.6%
Shares Out	263.50M
PE Ratio	49.43
Forward PE	29.83
Dividend	0.15 (0.82%)
Ex-Dividend Date	Jul 16, 2025

Volume	29,926,112
Average Volume	3,806,428
Open	17.68
Previous Close	18.19
Day's Range	15.01 - 19.49
52-Week Range	11.03 - 24.66
Beta	0.58
RSI	61.09
Earnings Date	Apr 22, 2026

About Beijing Scitop Bio-tech

Beijing Scitop Bio-tech Co., Ltd. researches, develops, produces, and sells probiotic, postbiotics, and microecologival preparations for animals and plants in China. It provides probiotic and postbiotics for gastrointestinal health, immune regulation, oral health, sleep aid and stress relief, women’s health, slimming and fat reduction, kidney and liver protection, blood sugar regulation, allergy relief, blood pressure regulation, and mother-infant transmission, as well as exercise, bone, heart, and skin health applications. The company also off...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 295
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300858

Financial Performance

In 2024, Beijing Scitop Bio-tech's revenue was 302.79 million, an increase of 1.19% compared to the previous year's 299.24 million. Earnings were 94.36 million, an increase of 0.94%.